Posted by Michael Wonder on 27 Sep 2016
Idelvion now registered in Australia
27 September 2016 - CSL Behring's Idelvion is now approved by the TGA.
The TGA approved Idelvion (albutrepenonacog alfa) on 20 September 2016 for use in all patients with haemophilia B for:
- Routine prophylaxis to prevent or reduce the frequency of bleeding episodes
- Control and prevention of bleeding episodes
- Control and prevention of bleeding in the perioperative setting
